Picture of Ping An Healthcare and Technology logo

1833 — Ping An Healthcare and Technology News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareHighly SpeculativeMid CapNeutral

China's Ping An Healthcare H1 revenue profit jumps on corporate client base expansion

China's Ping An Healthcare H1 revenue profit jumps on corporate client base expansion


Overview

  • China digital health platform's interim H1 revenue fell 0.7% yr/yr to RMB2.48 bln

  • Profit attributable to shareholders rose 63.5% yr/yr to RMB219 mln

  • Adjusted net profit increased 37.7% yr/yr, driven by improved business quality and revenue mix


Outlook

  • Ping An Healthcare plans to use HK$544.9 mln of unutilized placing proceeds by Dec 31, 2028 for investments, acquisitions and overseas expansion


Result Drivers

  • CORPORATE HEALTH MANAGEMENT - Revenue from corporate health management rose 65.1% yr/yr with the segment accounting for a greater share of total revenue, driven by expansion of the corporate client base and product diversification

  • AI AND TECHNOLOGY INVESTMENT - Company said ongoing investment in AI and digital operations improved service efficiency and contributed to gross profit growth

  • INSURANCE + HEALTH CARE SYNERGY - Upgrades to the insurance + health care synergistic model and expanded membership benefits supported customer retention and product competitiveness


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Revenue

RMB 2.48 bln

H1 Net Income Attributable

RMB 219.30 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for Ping AN Healthcare and Technology Co Ltd is HK$14.50, about 95.9% above its August 17 closing price of HK$7.40

  • The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 41 three months ago


Reuters Recommended Reads

  • Aug 17 - China Medical System H1 revenue rises on jump in sales of innovative and exclusive products

  • Aug 17 - Vaccine maker Sinovac H1 revenue rises on overseas growth, approvals

  • Aug 17 - Mobile healthcare provider DocGo's Q2 revenue misses on wind-down of migrant programs


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Ping An Healthcare and Technology

See all news